BIOMAT Database Logo BIOMAT Database Logo

Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis. 2019

Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
a Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University , Chongqing , China.

Osteoarthritis (OA) is a major public health concern for which a reliable non-invasive treatment option has yet to be developed. In the present study, we investigated the effects of saxagliptin, a novel dipeptidyl peptidase IV (DPP-4) inhibitor, on several important aspects of the pathophysiology of OA using primary human chondrocytes. The results of real-time PCR and ELISA analyses show that saxagliptin treatment significantly decreased mRNA and protein expression of three key cartilage degrading enzymes: matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13. The results of western blot confirmed that this decrease in MMP-1, -3, and -13 expression prevented degradation of type II collagen. We also found that saxagliptin significantly inhibited expression of a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS)-4 and ADAMTS-5, which was reflected by markedly decreased degradation of aggrecan. Inhibition of DPP-4 by saxagliptin also reduced oxidative stress in human primary chondrocytes as evidenced by decreased production of reactive oxygen species (ROS) and increased glutathione (GSH) levels. Additionally, the results of western blot analysis show that the effects of saxagliptin are mediated through the p38/IκBα/NF-κB pathway, which is considered an important treatment target for OA. These findings suggest a potential role for saxagliptin as a novel treatment against OA.

UI MeSH Term Description Entries
D010003 Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. Arthritis, Degenerative,Osteoarthrosis,Osteoarthrosis Deformans,Arthroses,Arthrosis,Arthritides, Degenerative,Degenerative Arthritides,Degenerative Arthritis,Osteoarthritides,Osteoarthroses
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071116 ADAMTS5 Protein An ADAMTS protease that contains two C-terminal thrombospondin (TS) motifs. It functions primarily as an aggrecanase, cleaving AGGRECAN in CARTILAGE, and may be involved in the destruction of aggrecan in ARTHRITIS. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Protein,ADAMTS-5 Protein,ADAMTS11 Protein,ADAMTS5 Protease,Aggrecanase-2,ADAMTS 5 Protein,Aggrecanase 2
D000071121 ADAMTS4 Protein An ADAMTS protease similar to ADAMTS5 PROTEIN. It contains a single C-terminal thrombospondin (TS) motif and cleaves AGGRECAN in CARTILAGE. It may also be involved in the destruction of aggrecan in ARTHRITIS. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 Protein,ADAMTS-4 Protein,Aggrecanase-1,ADAMTS 4 Protein,Aggrecanase 1
D000072000 NF-KappaB Inhibitor alpha An I-kappa B protein that inhibits the activity of dimeric NF-KAPPA B P50-REL complexes, sequesters transcription factor NF-kappaB as an inactive complex in the cytoplasm; and prevents NF-kappaB nuclear translocation and DNA binding. I Kappa B-alpha Protein,IKappaB-alpha,IKappaBalpha,Major Histocompatibility Complex Enhancer-Binding Protein MAD3,p40 Protein (IKappaB-alpha),I Kappa B alpha Protein,IKappaB alpha,Inhibitor alpha, NF-KappaB,Major Histocompatibility Complex Enhancer Binding Protein MAD3,NF KappaB Inhibitor alpha,alpha, NF-KappaB Inhibitor
D000218 Adamantane A tricyclo bridged hydrocarbon. Diamantane
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB

Related Publications

Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Salicin inhibits AGE-induced degradation of type II collagen and aggrecan in human SW1353 chondrocytes: therapeutic potential in osteoarthritis.
December 2019, Artificial cells, nanomedicine, and biotechnology,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis.
January 2019, American journal of translational research,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Activation of GPR40 Suppresses AGE-Induced Reduction of Type II Collagen and Aggrecan in Human SW1353 Chondrocytes.
January 2020, Drug design, development and therapy,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Cabozantinib prevents AGEs-induced degradation of type 2 collagen and aggrecan in human chondrocytes.
December 2023, Aging,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
WISP3-dependent regulation of type II collagen and aggrecan production in chondrocytes.
February 2004, Arthritis and rheumatism,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Activation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) inhibits degradation of type II collagen and aggrecan in human chondrocytes.
August 2019, European journal of pharmacology,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Cilostazol prevents the degradation of collagen type II in human chondrocytes.
August 2014, Biochemical and biophysical research communications,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
[Metabolic activation of chondrocytes in human osteoarthritis. Expression of type II collagen].
January 1999, Zeitschrift fur Orthopadie und ihre Grenzgebiete,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Discoordinate gene expression of aggrecan and type II collagen in experimental osteoarthritis.
March 1995, Arthritis and rheumatism,
Ning Hu, and Xuan Gong, and Shijie Yin, and Qi Li, and Hao Chen, and Yuwan Li, and Feilong Li, and Leilei Qing, and Jianye Yang, and Sizheng Zhu, and Jiawei Wang, and Junchao Li
Effects of FGF-2 and FGF receptor antagonists on MMP enzymes, aggrecan, and type II collagen in primary human OA chondrocytes.
January 2015, Scandinavian journal of rheumatology,
Copied contents to your clipboard!